Quick Answer
Jazz Pharmaceuticals plc reported Revenue (ASC 606) of $4.27 billion for fiscal year 2025.
Jazz Pharmaceuticals plc Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $4.27B | +4.9% |
| 2024 | $4.07B | +6.1% |
| 2023 | $3.83B | +4.8% |
| 2022 | $3.66B | +18.3% |
| 2021 | $3.09B | +30.9% |
| 2020 | $2.36B | +9.3% |
| 2019 | $2.16B | +14.3% |
| 2018 | $1.89B | +16.8% |
| 2017 | $1.62B | +8.8% |
| 2016 | $1.49B | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.13B | +6.7% | +7.7% |
| June 30, 2025 | $1.05B | +2.1% | +16.5% |
| March 31, 2025 | $897.84M | -0.5% | -14.9% |
| September 30, 2024 | $1.05B | +8.5% | +3.0% |
| June 30, 2024 | $1.02B | +6.9% | +13.5% |
| March 31, 2024 | $901.98M | +1.0% | -7.2% |
| September 30, 2023 | $972.14M | +3.3% | +1.5% |
| June 30, 2023 | $957.32M | +2.6% | +7.2% |
- Jazz Pharmaceuticals plc showed an increase of +4.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Jazz Pharmaceuticals plc’s revenue (asc 606) has grown by 186.8% (from $1.49 billion to $4.27 billion).
- The most recent figure is from Jazz Pharmaceuticals plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: